It’s strange that this story didn’t generate more hype. I wonder if many people missed it because it’s behind a paywall?
Last time there was a similar story in Kauppalehti, the share price rose 18 percent!
14 Likes
Continuing the wish list…..
In the Inderes interview, it would now be desirable to bring up India as well. Optomed and partner Aimil / Nextgen esolutions have projects ongoing there.
The question is, what is going on and at what stage, when will operations start or have they already started? Lumo AI / Aurora AI?
Hospital and other healthcare partners / customers with whom they work or where operations will start?
Information about India is requested.
Ville on a trip to India.
9 Likes
And about China, we also want to know how things are going there. Is revenue starting to come in yet?
7 Likes
I’ve been thinking for two weeks now whether I should put my hand in my pocket and add (heavily) to Optomed before the release. The discussion about these 1,200 deployments initially even stirred up some dormant FOMO, but my thinking eventually shifted to a more critical look at the situation.
If I remember correctly, one of the biggest promises of the handheld device was that it could be used in several (even dozens of) different units of the same provider. Of course, hundreds of home visits can be made with one device, and thousands over the years. Is each of these a new deployment?
I’m just trying to say that for a moment I (too?) happily confused sales and deployment figures. It’s certainly possible that they are the same thing and Optomed has sold 1,200+ devices. Possible, maybe. Most likely very improbable.
Another thing that somehow stuck in my mind was this quote from Himberg in a recent Kaleva article (Feb 2, 2026):
This doesn’t quite sound like devices are being snatched out of the salesmen’s hands. Rather the opposite. 1,200 devices sold by the end of the year would, in my opinion, be a smashing success in itself.
I held my fire this time.
I am looking forward with great interest to the upcoming report lurking around the corner, especially the sales figures for the devices segment (as well as expectations for 2026).
I may have made a big mistake by letting FUD take over. Somehow it just feels like this positive news and light hype are setting the stage for a small “disappointment” (relative to investors’ optimistic hopes) in the upcoming release. In the short term, that is; I’m not losing my faith in the company (at least not yet).
For now, I’m holding onto what I own and still looking for potential buying opportunities.
8 Likes
An interesting interview/podcast with Dr. Alvin Liu.
The Digital Healthcare Experience - Eye-Opening AI: Visionary Screening and Diagnosis
Listening to the podcast will certainly provide new insight into the significance (in the workflow) and scale (in cost savings) of the Epic integration previously announced by Aeye Health:
”Through this seamless integration, healthcare providers can now order an AI diabetic retinopathy exam directly from the patient chart. A nurse or medical assistant captures a single retinal image per eye using a portable camera integrated with AEYE-DS, and results are automatically returned to the patient’s medical record within seconds. When signs of disease are detected, an automated alert is sent to ophthalmology for timely follow-up. The entire process - from order to results - takes less than one minute. Full automation of reimbursement code billing and care gap reporting is also supported.”
28 Likes
Dr. T. Y. Alvin Liu works at the Johns Hopkins Medicine health system in the United States. He is the inaugural Director of the James P. Gills Jr. and Heather Gills AI Innovation Center and Assistant Professor of Ophthalmology at the Wilmer Eye Institute – Johns Hopkins School of Medicine. He is also a clinical retinal surgeon and leads research and implementation projects related to the use of health technology and AI within Hopkins => could AEYE Health be a customer?
12 Likes
Tuesday is knocking on the door soon, and it’s time for the annual review. Let’s check the forum’s expectations for Q4 and for this year.
Q4 revenue
- 3.5-4 million
- 4-4.5 million
- 4.5-5 million
- 5-5.5 million
- 5.5-6 million
0
äänestäjää
Revenue growth for this year
- 10-15%
- 15-20%
- 20-25%
- 25% or more
0
äänestäjää
1 Like
I happened to ask Gemini which information system CVS Health uses. Although it was already known without asking…
And the answer:
“““““““““““
Here is a summary of the system’s use across different units:
-
MinuteClinic: CVS’s walk-in clinics switched to using the EpicCare EMR system as early as 2015.
-
CVS Specialty & Care Management: Epic was implemented in 2017 to support care management for chronic and rare diseases.
-
Oak Street Health: The primary care network acquired by CVS in 2023 is currently transitioning to the Epic platform, and the transition is estimated to be completed by the second quarter of 2026.
-
Patient Portal: Customers can view their information through the CVS Health MyChart website, which is a patient portal belonging to Epic.
The use of Epic enables seamless information exchange between CVS and other major healthcare providers, as it is the most widely used EHR system in the United States.
““““““““““
There are 1,000 or even more of those MinuteClinic units. Additionally, CVS Health has its own pharmacy chain with a modest 9,000 pharmacies. Waiting for news…
10 Likes
I wonder to what extent AEYE’s agreement with Ford Medical could push that package forward…. It’s been really quiet on that front (too). The partnership announcement was made back in July, after all…..
1 Like
The M&A market continues to run hot. Conglomerate AMETEK, which generates 7.5 billion in revenue, has acquired LKC Technologies, the manufacturer of the portable RETeval camera. AMETEK already owns Reichert, a competitor to icare’s tonometers.
Portable devices clearly interest even the big players, and in this regard, AMETEK is a noteworthy competitor for Topcon in the acquisition market as well. No doubt there would be suitors for Optomed too.
https://investors.ametek.com/news-releases/news-release-details/ametek-acquires-lkc-technologies
34 Likes
Yes, Aeye Health is constantly promoting Aurora+DS rather than Topcon’s desktop camera..
25 Likes
30 Likes
On Tuesday, @Juha_Kinnunen, it would be at the very least interesting to hear about this Aeye Health Epic case from Optomed’s perspective. Has this been a bottleneck for the scaling of Aurora Aeye? What kind of doors does this open / how much will it accelerate the scaling of existing pilots, etc.? AEYE Health Expands Epic Integration for Portable Fully-Autonomous AI Eye Screening Across the US Healthcare System
8 Likes
Ping @Juha_Kinnunen, a few questions for the Optomed interview:
-
The significance of ISO 27001. Has the lack of it been an obstacle to securing contracts?
-
USA: The significance of the Epic integration in AEYE Health’s press release. Is the integration a new thing, and what are the effects and benefits of the Epic integration for client organizations from a workflow perspective? What is the sales situation for Lumo in the USA?
-
Progress of the project in China: have pilots been started? Are there any missing permits or approvals in China that would affect the progress of the project?
-
EU: Lumo+Aireen: are customer pilots starting? Are sales permits being sought for the Aireen+Lumo combination outside the EU?
-
Status of the Toku Eyes collaboration? Does the sale of Toku Eyes to Topcon affect the collaboration?
-
The situation in South Africa, has business progressed there? (Aeyeconnect has been advertising the soon-to-start launch of the service in Africa since the autumn. https://www.instagram.com/aeyeconnect/)
-
Kristiina Leppänen is joining the Board of Directors as a new member. What are the objectives behind expanding the board and bringing in new expertise?
-
A sales permit for Optomed Lumo has been applied for and granted in Canada. What is the Canadian market situation like from Optomed’s perspective?
22 Likes
-Is there any new information regarding negotiations with Big Pharma that could be shared with shareholders?
-The situation in India, has a foothold already been gained?
-What was the impact of the weakening dollar on the last quarter’s result?
-Is the software side recovering from last year’s slump?
15 Likes
Found this on the Kauppalehti forum. Super photos with a super camera ….. Lumo. 
Edit.
That Emilio Llado seems to be a Doctor of Optometry (OD) in addition to his other titles.
8 Likes
@Optis have you had a chance to handle Lumo yet? Since you have experience with the Aurora camera, at least on a trial basis. It would be nice to hear your comments if you have any.
7 Likes
Yes, I tried Aurora for testing at the Finnish Medical Convention (Lääkäripäivät), but I haven’t tried Lumo. I’m on board as a shareholder, so I have confidence in the company—hopefully still after tomorrow as well.
41 Likes
Results out - nothing to cheer about.
9 Likes
That depends entirely on what you read there. I have been waiting for this:
“Aurora AEYE-based revenue has grown in every quarter this year, and growth has accelerated particularly in the second half of the year.”
Going forward, ISO certification and the continued status as the sole approved handheld camera will increase this further. I don’t know about the market reaction, as the impatient ones seem to expect some utopian figures, but with this information, I am happy with my buys and can comfortably continue buying this year as well.
23 Likes